

Datasheet for ABIN7275837

VEGFR2/CD309 Protein (AA 20-764) (His-Avi Tag)**3** Images[Go to Product page](#)

Overview

| | |
|-------------------------------|---|
| Quantity: | 100 µg |
| Target: | VEGFR2/CD309 (VEGFR2) |
| Protein Characteristics: | AA 20-764 |
| Origin: | Human |
| Source: | HEK-293 Cells |
| Protein Type: | Recombinant |
| Purification tag / Conjugate: | This VEGFR2/CD309 protein is labelled with His-Avi Tag. |

Product Details

| | |
|------------------------------|---|
| Purpose: | Human VEGF R2/KDR Protein |
| Sequence: | Ala20-Glu764 |
| Characteristics: | Recombinant Human VEGF R2/KDR Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Ala20-Glu764. |
| Purity: | > 95 % as determined by Tris-Bis PAGE, > 95 % as determined by HPLC |
| Sterility: | 0.22 µm filtered |
| Endotoxin Level: | Less than 1EU per µg by the LAL method. |
| Biological Activity Comment: | Immobilized Human VEGF R2 at 0.5µg/ml (100µl/Well). Dose response curve for Anti-VEGFR2 Antibody, hFc Tag with the EC50 of 23.1ng/ml determined by ELISA. See testing image for detail. |

Target Details


| | |
|-------------------|---|
| Target: | VEGFR2/CD309 (VEGFR2) |
| Alternative Name: | VEGF R2 (VEGFR2 Products) |
| Background: | Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. The tyrosine kinase receptor vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulator of angiogenesis. |
| Molecular Weight: | 86.2 kDa. Due to glycosylation, the protein migrates to 115-140 kDa based on Tris-Bis PAGE result. |
| Pathways: | RTK Signaling , Glycosaminoglycan Metabolic Process , Signaling Events mediated by VEGFR1 and VEGFR2 , Growth Factor Binding , Regulation of long-term Neuronal Synaptic Plasticity , VEGF Signaling |

Application Details

| | |
|---------------|-----------------------|
| Restrictions: | For Research Use only |
|---------------|-----------------------|


Handling

| | |
|------------------|---|
| Format: | Lyophilized |
| Reconstitution: | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/mL is recommended. Dissolve the lyophilized protein in distilled water. |
| Buffer: | Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization. |
| Storage: | -20 °C,-80 °C |
| Storage Comment: | -20 to -80°C for 12 months as supplied from date of receipt., -80°C for 3-6 months after reconstitution., 2-8°C for 2-7 days after reconstitution., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Expiry Date: | 12 months |



SDS-PAGE


Image 1. Human VEGF R2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95 % .



Size-exclusion chromatography-High Pressure Liquid Chromatography

Image 2. The purity of Human VEGF R2 is greater than 95 % as determined by SEC-HPLC.

Human VEGF R2, His Tag ELISA
0.05µg Human VEGF R2, His Tag Per Well



ELISA

Image 3. Immobilized Human VEGF R2 at 0.5 µg/mL (100 µ L/Well). Dose response curve for Anti-VEGF R2 Antibody, hFc Tag with the EC50 of 23.1 ng/mL determined by ELISA.